• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1.源自感染1型人类免疫缺陷病毒非B亚型个体细胞的人抗V3单克隆抗体的跨亚型中和活性
J Virol. 2006 Jul;80(14):6865-72. doi: 10.1128/JVI.02202-05.
2
The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1.一种人源单克隆抗体的跨亚型中和活性由1型人类免疫缺陷病毒的GPGR V3基序决定。
AIDS Res Hum Retroviruses. 2004 Nov;20(11):1254-8. doi: 10.1089/aid.2004.20.1254.
3
Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1.决定源自感染1型人类免疫缺陷病毒A亚型或B亚型毒株的受试者的V3特异性人单克隆抗体中和广度和效力的因素。
J Virol. 2006 Jul;80(14):7127-35. doi: 10.1128/JVI.02619-05.
4
Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.对V3构象敏感表位具有特异性的人源单克隆抗体可中和来自不同进化枝的1型人类免疫缺陷病毒原始分离株。
J Virol. 2002 Sep;76(18):9035-45. doi: 10.1128/jvi.76.18.9035-9045.2002.
5
Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity.相对于其表位精细特异性而言,针对HIV-1 gp120 V3环区的抗体的中和活性。
Virology. 2008 Nov 25;381(2):251-60. doi: 10.1016/j.virol.2008.08.032. Epub 2008 Sep 26.
6
A human monoclonal antibody specific for the V3 loop of HIV type 1 clade E cross-reacts with other HIV type 1 clades.一种针对1型人类免疫缺陷病毒(HIV-1)E亚型V3环的人源单克隆抗体与其他1型HIV亚型发生交叉反应。
AIDS Res Hum Retroviruses. 1998 Feb 10;14(3):213-21. doi: 10.1089/aid.1998.14.213.
7
Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking.对人类免疫缺陷病毒1型A亚型和B亚型V3结构域具有交叉反应性的抗体在喀麦隆患者血清中很常见,但其中和活性通常受到表位掩盖的限制。
J Virol. 2005 Jan;79(2):780-90. doi: 10.1128/JVI.79.2.780-790.2005.
8
Production and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors.从感染 HIV-1 的印度供体的细胞中生产和鉴定人抗 V3 单克隆抗体。
Virol J. 2012 Sep 12;9:196. doi: 10.1186/1743-422X-9-196.
9
Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope.通过将免疫反应聚焦于一个中和表位在兔体内诱导产生的针对HIV-1的跨亚型中和抗体。
Virology. 2009 Sep 15;392(1):82-93. doi: 10.1016/j.virol.2009.05.039. Epub 2009 Jul 26.
10
Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes.抗 V3 单克隆抗体对多种 HIV-1 亚型表现出广泛的中和活性。
PLoS One. 2010 Apr 21;5(4):e10254. doi: 10.1371/journal.pone.0010254.

引用本文的文献

1
Development of a Virus Particle-Based Antibody-Dependent Cellular Phagocytosis (ADCP) Assay for HIV.一种基于病毒颗粒的HIV抗体依赖性细胞吞噬作用(ADCP)检测方法的开发
bioRxiv. 2025 Sep 1:2025.08.27.672700. doi: 10.1101/2025.08.27.672700.
2
Neutralizing antibodies elicited in macaques recognize V3 residues on altered conformations of HIV-1 Env trimer.猕猴体内产生的中和抗体可识别HIV-1包膜三聚体构象改变时的V3残基。
NPJ Vaccines. 2024 Dec 5;9(1):240. doi: 10.1038/s41541-024-01038-0.
3
Signal peptide exchange alters HIV-1 envelope antigenicity and immunogenicity.信号肽交换改变 HIV-1 包膜抗原性和免疫原性。
Front Immunol. 2024 Sep 24;15:1476924. doi: 10.3389/fimmu.2024.1476924. eCollection 2024.
4
Broadly neutralizing antibody epitopes on HIV-1 particles are exposed after virus interaction with host cells.HIV-1 粒子上的广谱中和抗体表位在病毒与宿主细胞相互作用后暴露。
J Virol. 2023 Sep 28;97(9):e0071023. doi: 10.1128/jvi.00710-23. Epub 2023 Sep 8.
5
Dual Role of HIV-1 Envelope Signal Peptide in Immune Evasion.HIV-1 包膜信号肽的双重免疫逃逸作用。
Viruses. 2022 Apr 13;14(4):808. doi: 10.3390/v14040808.
6
High-Throughput B Cell Epitope Determination by Next-Generation Sequencing.高通量 B 细胞表位测定的下一代测序技术。
Front Immunol. 2022 Mar 23;13:855772. doi: 10.3389/fimmu.2022.855772. eCollection 2022.
7
Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice.针对 HIV-1 包膜免疫原区域的非中和抗体可降低人源化小鼠的粘膜感染和病毒载量。
PLoS Pathog. 2022 Jan 5;18(1):e1010183. doi: 10.1371/journal.ppat.1010183. eCollection 2022 Jan.
8
Distinct conformations of the HIV-1 V3 loop crown are targetable for broad neutralization.HIV-1 V3环冠的不同构象可成为广泛中和作用的靶点。
Nat Commun. 2021 Nov 18;12(1):6705. doi: 10.1038/s41467-021-27075-0.
9
Signal peptide of HIV-1 envelope modulates glycosylation impacting exposure of V1V2 and other epitopes.HIV-1 包膜的信号肽调节糖基化,影响 V1V2 及其他表位的暴露。
PLoS Pathog. 2020 Dec 28;16(12):e1009185. doi: 10.1371/journal.ppat.1009185. eCollection 2020 Dec.
10
Development of a 3Mut-Apex-Stabilized Envelope Trimer That Expands HIV-1 Neutralization Breadth When Used To Boost Fusion Peptide-Directed Vaccine-Elicited Responses.开发一种 3Mut-Apex-Stabilized 包膜三聚体,当用于增强融合肽指导的疫苗诱导的反应时,可扩大 HIV-1 中和广度。
J Virol. 2020 Jun 16;94(13). doi: 10.1128/JVI.00074-20.

本文引用的文献

1
Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1.决定源自感染1型人类免疫缺陷病毒A亚型或B亚型毒株的受试者的V3特异性人单克隆抗体中和广度和效力的因素。
J Virol. 2006 Jul;80(14):7127-35. doi: 10.1128/JVI.02619-05.
2
Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies.来自急性和早期B亚型感染的1型人类免疫缺陷病毒env克隆,用于疫苗诱导中和抗体的标准化评估。
J Virol. 2005 Aug;79(16):10108-25. doi: 10.1128/JVI.79.16.10108-10125.2005.
3
Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.两种广泛中和HIV-1抗体中的心磷脂多特异性自身反应性。
Science. 2005 Jun 24;308(5730):1906-8. doi: 10.1126/science.1111781. Epub 2005 Apr 28.
4
Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking.对人类免疫缺陷病毒1型A亚型和B亚型V3结构域具有交叉反应性的抗体在喀麦隆患者血清中很常见,但其中和活性通常受到表位掩盖的限制。
J Virol. 2005 Jan;79(2):780-90. doi: 10.1128/JVI.79.2.780-790.2005.
5
The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1.一种人源单克隆抗体的跨亚型中和活性由1型人类免疫缺陷病毒的GPGR V3基序决定。
AIDS Res Hum Retroviruses. 2004 Nov;20(11):1254-8. doi: 10.1089/aid.2004.20.1254.
6
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies.一组抗1型人类免疫缺陷病毒单克隆抗体的全面跨谱系中和分析
J Virol. 2004 Dec;78(23):13232-52. doi: 10.1128/JVI.78.23.13232-13252.2004.
7
Infection with HIV type 1 group M non-B subtypes in individuals living in New York City.居住在纽约市的个体感染1型人类免疫缺陷病毒M组非B亚型的情况。
J Acquir Immune Defic Syndr. 2004 Jul 1;36(3):835-44. doi: 10.1097/00126334-200407010-00011.
8
The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection.gp120的V1/V2结构域是原发性人类免疫缺陷病毒1型分离株对感染后通常诱导产生的抗体中和敏感性的全局调节因子。
J Virol. 2004 May;78(10):5205-15. doi: 10.1128/jvi.78.10.5205-5215.2004.
9
The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.v3环在大多数1型人类免疫缺陷病毒原始分离株的表面是可及的,并作为一个中和表位。
J Virol. 2004 Mar;78(5):2394-404. doi: 10.1128/jvi.78.5.2394-2404.2004.
10
Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D.人源单克隆抗体447-52D对HIV-1广泛中和的结构原理
Structure. 2004 Feb;12(2):193-204. doi: 10.1016/j.str.2004.01.003.

源自感染1型人类免疫缺陷病毒非B亚型个体细胞的人抗V3单克隆抗体的跨亚型中和活性

Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1.

作者信息

Gorny Miroslaw K, Williams Constance, Volsky Barbara, Revesz Kathy, Wang Xiao-Hong, Burda Sherri, Kimura Tetsuya, Konings Frank A J, Nádas Arthur, Anyangwe Christopher A, Nyambi Phillipe, Krachmarov Chavdar, Pinter Abraham, Zolla-Pazner Susan

机构信息

Department of Pathology, New York University School of Medicine, New York, New York 10016, USA.

出版信息

J Virol. 2006 Jul;80(14):6865-72. doi: 10.1128/JVI.02202-05.

DOI:10.1128/JVI.02202-05
PMID:16809292
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1489067/
Abstract

The majority of global human immunodeficiency virus infections are caused by viruses characterized by a GPGQ motif at the tip of the V3 loop. Characterization of anti-V3 monoclonal antibodies (MAbs) that neutralize isolates with the GPGQ V3 motif is an important step in designing vaccines that will induce such Abs. Consequently, seven human anti-V3 MAbs derived from the cells of individuals infected with non-B-subtype viruses (anti-V3(non-B) MAbs) were generated from the cells of individuals from Africa infected with circulating recombinant forms CRF02_AG, CRF09_cpx, and CRF13_cpx, each of which contains a subtype A env gene. Sequence analysis of plasma viruses revealed a GPGQ motif at the apex of the V3 loop from six of the seven subjects and a GPGR motif from one subject. The MAbs were selected with fusion proteins (FP) containing V3(92UG037.8) or V3(JR-CSF) from subtype A or B, respectively. In virus binding assays, five of the seven (71%) anti-V3(non-B) MAbs bound to V3-FPs from both subtype A and subtype B, while only four of the nine (44%) anti-V3(B) MAbs recognized both V3-FPs. Using two neutralization assays, both the anti-V3(non-B) and the anti-V3(B) MAbs neutralized subtype B viruses with similar activities, while the anti-V3(non-B) MAbs exhibited a tendency toward both increased potency and breadth of neutralization against non-B viruses compared to anti-V3(B) MAbs. Statistical significance was not achieved, due in large measure to the sizes of the MAb panels, but the overall pattern of data strongly suggests that viruses with the GPGQ motif at the tip of the V3 loop induce anti-V3 Abs with broader cross-neutralizing activity than do viruses with the GPGR motif.

摘要

全球大多数人类免疫缺陷病毒感染是由V3环顶端具有GPGQ基序特征的病毒引起的。鉴定能够中和具有GPGQ V3基序分离株的抗V3单克隆抗体(MAb)是设计能诱导此类抗体的疫苗的重要一步。因此,从感染了循环重组形式CRF02_AG、CRF09_cpx和CRF13_cpx的非洲个体细胞中产生了七种源自感染非B亚型病毒个体细胞的人抗V3 MAb(抗V3(non-B) MAb),每种循环重组形式都包含一个A亚型env基因。血浆病毒的序列分析显示,七名受试者中有六名的V3环顶端存在GPGQ基序,一名受试者存在GPGR基序。这些MAb分别用含有A亚型或B亚型的V3(92UG037.8)或V3(JR-CSF)的融合蛋白(FP)筛选。在病毒结合试验中,七种抗V3(non-B) MAb中有五种(71%)与A亚型和B亚型的V3-FP结合,而九种抗V3(B) MAb中只有四种(44%)能识别两种V3-FP。使用两种中和试验,抗V3(non-B) MAb和抗V3(B) MAb对B亚型病毒的中和活性相似,而与抗V3(B) MAb相比,抗V3(non-B) MAb对非B病毒的中和效力和广度有增加的趋势。由于MAb组的规模,未达到统计学显著性,但数据的总体模式强烈表明,V3环顶端具有GPGQ基序的病毒比具有GPGR基序的病毒诱导的抗V3抗体具有更广泛的交叉中和活性。